For virkning og sikkerhed hos patienter < 18 år foreligger kun begrænset dokumentation, hvorfor anvendelse af < (HANDELSNAVN) > ikke anbefales til disse patienter.
After an assessment of the documentation provided by the MAH and an evaluation of the current EU- wide clinical practices relating to the use of Pravachol the following was considered to be the most suitable harmonised Section 4.2 Posology text: